Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBYN DAWN HARTVICKSON

Allopathic & Osteopathic Physicians Family Medicine

NPI
1679532659
CMS profile
303021
Location
NEWTON, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$867.92

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $867.92 59

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBYN DAWN HARTVICKSON

NPI 1679532659 · CMS profile ID 303021

Allopathic & Osteopathic Physicians / Family Medicine

NEWTON, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679532659?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679532659?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679532659?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1679532659?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $867.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $14.8712/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765185 CMS
AbbVie Inc. $21.0012/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765181 CMS
AbbVie Inc. $10.0712/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765177 CMS
AbbVie Inc. $20.4211/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765173 CMS
Abbott Laboratories $11.5611/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815804743 CMS
Lilly USA, LLC $13.6910/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818731483 CMS
PFIZER INC. $2.6110/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833182027 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.4010/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763619040 CMS
AbbVie Inc. $22.9210/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765169 CMS
PFIZER INC. $15.3910/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833587457 CMS
AbbVie Inc. $23.5409/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765165 CMS
Janssen Pharmaceuticals, Inc $15.3409/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788551581 CMS
Lilly USA, LLC $13.5809/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818694843 CMS
Novartis Pharmaceuticals Corporation $19.0309/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812712139 CMS
Merck Sharp & Dohme Corporation $11.3908/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848662471 CMS
AbbVie Inc. $7.7608/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765161 CMS
PFIZER INC. $5.5208/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833182031 CMS
AbbVie Inc. $13.2407/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765157 CMS
AbbVie Inc. $14.2907/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765154 CMS
Merck Sharp & Dohme Corporation $12.1707/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848642655 CMS
Biohaven Pharmaceuticals, Inc. $17.8407/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852513129 CMS
Pacira Therapeutics, Inc. $16.9507/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838727363 CMS
AbbVie Inc. $14.5607/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765151 CMS
AbbVie Inc. $3.9207/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765147 CMS
PFIZER INC. $1.5006/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833182035 CMS
Merck Sharp & Dohme Corporation $15.5106/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848499241 CMS
Biohaven Pharmaceuticals, Inc. $19.1606/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852513127 CMS
Amgen Inc. $19.4906/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825741533 CMS
Janssen Pharmaceuticals, Inc $11.2006/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788551583 CMS
AbbVie Inc. $3.5805/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765141 CMS
Novartis Pharmaceuticals Corporation $16.8505/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812712137 CMS
Amarin Pharma Inc. $18.4205/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815252683 CMS
AbbVie Inc. $5.0205/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765137 CMS
Biohaven Pharmaceuticals, Inc. $18.0605/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852513125 CMS
AbbVie Inc. $12.2405/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765133 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.5505/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819966585 CMS
AbbVie Inc. $3.0105/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765129 CMS
Daiichi Sankyo Inc. $18.0405/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836289563 CMS
AbbVie Inc. $23.6505/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765125 CMS
AbbVie Inc. $6.0004/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765121 CMS
AbbVie Inc. $23.2204/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765118 CMS
Novartis Pharmaceuticals Corporation $13.4804/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812712135 CMS
AbbVie Inc. $20.7004/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765115 CMS
Lilly USA, LLC $13.8004/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818732169 CMS
AbbVie Inc. $15.5904/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794765111 CMS
Eisai Inc. $23.0204/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817895101 CMS
Daiichi Sankyo Inc. $14.8603/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836276007 CMS
Amarin Pharma Inc. $11.4303/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815252681 CMS
Novo Nordisk Inc $21.3502/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810714947 CMS
Amgen Inc. $15.5602/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825741529 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $349.87 24
PY2020 $259.38 18
PY2021 $867.92 59
PY2022 $1,012.70 73
PY2023 $2,574.33 71
PY2024 $862.16 54
PY2025 $813.93 47

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $136,207.90 39
PY2024 Principal investigator $344,898.92 54
PY2023 Principal investigator $702,129.77 95
PY2022 Principal investigator $153,146.27 62
PY2021 Principal investigator $143,310.07 45
PY2020 Principal investigator $223,270.91 168
PY2019 Principal investigator $302,825.41 141

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

141 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $1,216.80 12/20/2019 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669967663
Principal investigator 1 GlaxoSmithKline, LLC. $1,750.50 12/20/2019 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669967881
Principal investigator 1 GlaxoSmithKline, LLC. $1,100.70 11/26/2019 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669967875
Principal investigator 1 GlaxoSmithKline, LLC. $1,247.40 11/20/2019 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669974717
Principal investigator 1 Merck Sharp & Dohme Corporation $1,526.10 11/18/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691501143
Principal investigator 1 GlaxoSmithKline, LLC. $1,697.40 11/13/2019 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669967871
Principal investigator 1 GlaxoSmithKline, LLC. $1,950.30 10/30/2019 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669967231
Principal investigator 1 Merck Sharp & Dohme Corporation $97.64 10/30/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449155
Principal investigator 1 Merck Sharp & Dohme Corporation $1,261.20 10/28/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449145
Principal investigator 1 Merck Sharp & Dohme Corporation $7,300.50 10/16/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449151
Principal investigator 1 Merck Sharp & Dohme Corporation $14.08 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691497955
Principal investigator 1 Merck Sharp & Dohme Corporation $2.40 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691497960
Principal investigator 1 Merck Sharp & Dohme Corporation $2.80 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691497965
Principal investigator 1 Merck Sharp & Dohme Corporation $20.40 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691497969
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691497975
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691498293
Principal investigator 1 Merck Sharp & Dohme Corporation $39.60 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691498305
Principal investigator 1 Merck Sharp & Dohme Corporation $70.32 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691498309
Principal investigator 1 Merck Sharp & Dohme Corporation $739.20 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691498649
Principal investigator 1 Merck Sharp & Dohme Corporation $8.08 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691499841
Principal investigator 1 Merck Sharp & Dohme Corporation $82.50 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691499845
Principal investigator 1 Merck Sharp & Dohme Corporation $9.24 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691499849
Principal investigator 1 Merck Sharp & Dohme Corporation $9.68 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691499855
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691500187
Principal investigator 1 Merck Sharp & Dohme Corporation $26.60 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691501585
Principal investigator 1 Merck Sharp & Dohme Corporation $3.64 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691501929
Principal investigator 1 Merck Sharp & Dohme Corporation $338.80 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691501931
Principal investigator 1 Merck Sharp & Dohme Corporation $11.40 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691503247
Principal investigator 1 Merck Sharp & Dohme Corporation $20.40 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691533975
Principal investigator 1 Merck Sharp & Dohme Corporation $94.08 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691534359
Principal investigator 1 Merck Sharp & Dohme Corporation $39.60 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691534909
Principal investigator 1 Merck Sharp & Dohme Corporation $1.96 10/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691535457
Principal investigator 1 GlaxoSmithKline, LLC. $2,137.50 09/30/2019 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669964991
Principal investigator 1 Merck Sharp & Dohme Corporation $200.00 09/24/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691347731
Principal investigator 1 Merck Sharp & Dohme Corporation $11,935.62 09/11/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691401479
Principal investigator 1 Merck Sharp & Dohme Corporation $300.00 09/05/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691347735
Principal investigator 1 Merck Sharp & Dohme Corporation $130.00 09/05/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691348781
Principal investigator 1 Merck Sharp & Dohme Corporation $1,000.00 09/05/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691348783
Principal investigator 1 GlaxoSmithKline, LLC. $1,363.50 09/03/2019 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669965103
Principal investigator 1 GlaxoSmithKline, LLC. $1,656.90 08/27/2019 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669969409
Principal investigator 1 Merck Sharp & Dohme Corporation $14,744.46 08/09/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691401547
Principal investigator 1 Merck Sharp & Dohme Corporation $24.75 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691383731
Principal investigator 1 Merck Sharp & Dohme Corporation $252.00 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691383735
Principal investigator 1 Merck Sharp & Dohme Corporation $68.00 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691384029
Principal investigator 1 Merck Sharp & Dohme Corporation $0.68 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691384199
Principal investigator 1 Merck Sharp & Dohme Corporation $1.20 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691384273
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691384277
Principal investigator 1 Merck Sharp & Dohme Corporation $1,210.00 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691384283
Principal investigator 1 Merck Sharp & Dohme Corporation $13.00 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691384381
Principal investigator 1 Merck Sharp & Dohme Corporation $13.60 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691384385
Principal investigator 1 Merck Sharp & Dohme Corporation $1,980.00 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691384387
Principal investigator 1 Merck Sharp & Dohme Corporation $2.75 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691384391
Principal investigator 1 Merck Sharp & Dohme Corporation $4.84 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691384633
Principal investigator 1 Merck Sharp & Dohme Corporation $49.50 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691384637
Principal investigator 1 Merck Sharp & Dohme Corporation $49.50 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691384641
Principal investigator 1 Merck Sharp & Dohme Corporation $2,640.00 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691385013
Principal investigator 1 Merck Sharp & Dohme Corporation $275.00 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691385017
Principal investigator 1 Merck Sharp & Dohme Corporation $28.50 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691385021
Principal investigator 1 Merck Sharp & Dohme Corporation $33.00 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691385117
Principal investigator 1 Merck Sharp & Dohme Corporation $38.00 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691385121
Principal investigator 1 Merck Sharp & Dohme Corporation $4.04 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691385125
Principal investigator 1 Merck Sharp & Dohme Corporation $5.25 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691385131
Principal investigator 1 Merck Sharp & Dohme Corporation $65.89 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691385135
Principal investigator 1 Merck Sharp & Dohme Corporation $0.38 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691401047
Principal investigator 1 Merck Sharp & Dohme Corporation $95.00 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691401985
Principal investigator 1 Merck Sharp & Dohme Corporation $7.00 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691402031
Principal investigator 1 Merck Sharp & Dohme Corporation $7.50 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691402037
Principal investigator 1 Merck Sharp & Dohme Corporation $70.32 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691402039
Principal investigator 1 Merck Sharp & Dohme Corporation $71.25 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691402485
Principal investigator 1 Merck Sharp & Dohme Corporation $9.75 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691402491
Principal investigator 1 Merck Sharp & Dohme Corporation $907.50 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691402495
Principal investigator 1 Merck Sharp & Dohme Corporation $8.80 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691418713
Principal investigator 1 Merck Sharp & Dohme Corporation $336.00 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691420753
Principal investigator 1 Merck Sharp & Dohme Corporation $51.00 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691420843
Principal investigator 1 Merck Sharp & Dohme Corporation $10.00 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691421301
Principal investigator 1 Merck Sharp & Dohme Corporation $206.25 08/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691421313
Principal investigator 1 GlaxoSmithKline, LLC. $2,433.60 08/07/2019 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669967491
Principal investigator 1 GlaxoSmithKline, LLC. $1,420.60 07/24/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES
ROTA-081 No dispute reported 06/30/2026 669960449
Principal investigator 1 Merck Sharp & Dohme Corporation $75.00 07/22/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691370501
Principal investigator 1 SANOFI PASTEUR INC. $550.00 07/16/2019 Non-covered Recipient Entity
Alliance For Multispecialty Research,LLC
QHD04 Safety and Immunogenicity of Different Dosages of High Dose Quadrivalent Influenza Vaccine versus Standard Dose Quadrivalent Influenza Vaccine in Children 6 months to Less than 5 Years of Age No dispute reported 06/30/2026 691621983
Principal investigator 1 Merck Sharp & Dohme Corporation $9,762.81 07/10/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691401549
Principal investigator 1 Merck Sharp & Dohme Corporation $12,697.05 06/13/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691349563
Principal investigator 1 SANOFI PASTEUR INC. $398.00 06/13/2019 Non-covered Recipient Entity
Alliance For Multispecialty Research,LLC
QHD04 Safety and Immunogenicity of Different Dosages of High Dose Quadrivalent Influenza Vaccine versus Standard Dose Quadrivalent Influenza Vaccine in Children 6 months to Less than 5 Years of Age No dispute reported 06/30/2026 691619445
Principal investigator 1 Merck Sharp & Dohme Corporation $4.04 06/10/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691340069
Principal investigator 1 Merck Sharp & Dohme Corporation $4.84 06/10/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691340073
Principal investigator 1 Merck Sharp & Dohme Corporation $20.00 06/10/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691340935
Principal investigator 1 Merck Sharp & Dohme Corporation $70.32 06/10/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691341187
Principal investigator 1 Merck Sharp & Dohme Corporation $1.20 06/10/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691341481
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 06/10/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691341489
Principal investigator 1 Merck Sharp & Dohme Corporation $0.68 06/10/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691355827
Principal investigator 1 Merck Sharp & Dohme Corporation $0.38 06/10/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691358507
Principal investigator 1 Merck Sharp & Dohme Corporation $2.75 06/10/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372926
Principal investigator 1 SANOFI PASTEUR INC. $332.20 05/23/2019 Non-covered Recipient Entity
Alliance For Multispecialty Research,LLC
QHD04 Safety and Immunogenicity of Different Dosages of High Dose Quadrivalent Influenza Vaccine versus Standard Dose Quadrivalent Influenza Vaccine in Children 6 months to Less than 5 Years of Age No dispute reported 06/30/2026 691619793
Principal investigator 1 Merck Sharp & Dohme Corporation $11,899.29 05/15/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691315199
Principal investigator 1 Merck Sharp & Dohme Corporation $247.50 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691339997
Principal investigator 1 Merck Sharp & Dohme Corporation $26.27 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691340001
Principal investigator 1 Merck Sharp & Dohme Corporation $26.60 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691340231
Principal investigator 1 Merck Sharp & Dohme Corporation $1,633.50 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691340861
Principal investigator 1 Merck Sharp & Dohme Corporation $1,848.00 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691340867
Principal investigator 1 Merck Sharp & Dohme Corporation $192.50 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691340931
Principal investigator 1 Merck Sharp & Dohme Corporation $15.84 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691340993
Principal investigator 1 Merck Sharp & Dohme Corporation $156.75 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691340997
Principal investigator 1 Merck Sharp & Dohme Corporation $66.50 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691341119
Principal investigator 1 Merck Sharp & Dohme Corporation $7.00 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691341125
Principal investigator 1 Merck Sharp & Dohme Corporation $4.90 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691341147
Principal investigator 1 Merck Sharp & Dohme Corporation $4,356.00 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691341149
Principal investigator 1 Merck Sharp & Dohme Corporation $453.75 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691341215
Principal investigator 1 Merck Sharp & Dohme Corporation $847.00 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691341329
Principal investigator 1 Merck Sharp & Dohme Corporation $112.20 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691341485
Principal investigator 1 Merck Sharp & Dohme Corporation $47.60 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691341573
Principal investigator 1 Merck Sharp & Dohme Corporation $49.50 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691341577
Principal investigator 1 Merck Sharp & Dohme Corporation $54.45 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691341983
Principal investigator 1 Merck Sharp & Dohme Corporation $62.70 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691341989
Principal investigator 1 Merck Sharp & Dohme Corporation $21.45 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691343325
Principal investigator 1 Merck Sharp & Dohme Corporation $22.72 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691343331
Principal investigator 1 Merck Sharp & Dohme Corporation $23.10 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691343401
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691343405
Principal investigator 1 Merck Sharp & Dohme Corporation $11.55 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372199
Principal investigator 1 Merck Sharp & Dohme Corporation $235.20 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372606
Principal investigator 1 Merck Sharp & Dohme Corporation $148.50 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372741
Principal investigator 1 Merck Sharp & Dohme Corporation $49.50 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691396249
Principal investigator 1 Merck Sharp & Dohme Corporation $554.40 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691396339
Principal investigator 1 Merck Sharp & Dohme Corporation $9.10 05/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691396507
Principal investigator 1 SANOFI PASTEUR INC. $1,035.90 05/07/2019 Non-covered Recipient Entity
Alliance For Multispecialty Research,LLC
QHD04 Safety and Immunogenicity of Different Dosages of High Dose Quadrivalent Influenza Vaccine versus Standard Dose Quadrivalent Influenza Vaccine in Children 6 months to Less than 5 Years of Age No dispute reported 06/30/2026 691620587
Principal investigator 1 Merck Sharp & Dohme Corporation $17,501.05 04/12/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691315201
Principal investigator 1 SANOFI PASTEUR INC. $4,978.60 04/11/2019 Non-covered Recipient Entity
Alliance For Multispecialty Research,LLC
QHD04 Safety and Immunogenicity of Different Dosages of High Dose Quadrivalent Influenza Vaccine versus Standard Dose Quadrivalent Influenza Vaccine in Children 6 months to Less than 5 Years of Age No dispute reported 06/30/2026 691619969
Principal investigator 1 Merck Sharp & Dohme Corporation $70.32 04/08/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691341131
Principal investigator 1 Merck Sharp & Dohme Corporation $684.00 03/19/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691315333
Principal investigator 1 Merck Sharp & Dohme Corporation $32,999.01 03/14/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691315205
Principal investigator 1 SANOFI PASTEUR INC. $11,974.40 03/12/2019 Non-covered Recipient Entity
Alliance For Multispecialty Research,LLC
QHD04 Safety and Immunogenicity of Different Dosages of High Dose Quadrivalent Influenza Vaccine versus Standard Dose Quadrivalent Influenza Vaccine in Children 6 months to Less than 5 Years of Age No dispute reported 06/30/2026 691619741
Principal investigator 1 Merck Sharp & Dohme Corporation $342.00 02/28/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691326291
Principal investigator 1 Merck Sharp & Dohme Corporation $124.75 02/13/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691370495
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 02/07/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691316341
Principal investigator 1 SANOFI PASTEUR INC. $32,930.60 02/07/2019 Non-covered Recipient Entity
Alliance For Multispecialty Research,LLC
QHD04 Safety and Immunogenicity of Different Dosages of High Dose Quadrivalent Influenza Vaccine versus Standard Dose Quadrivalent Influenza Vaccine in Children 6 months to Less than 5 Years of Age No dispute reported 06/30/2026 691616083
Principal investigator 1 Merck Sharp & Dohme Corporation $8,626.80 02/05/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691316345
Principal investigator 1 Merck Sharp & Dohme Corporation $183.33 01/24/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691307719
Principal investigator 1 Merck Sharp & Dohme Corporation $11,414.10 01/23/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691311593
Principal investigator 1 SANOFI PASTEUR INC. $42,441.10 01/22/2019 Non-covered Recipient Entity
Alliance For Multispecialty Research,LLC
QHD04 Safety and Immunogenicity of Different Dosages of High Dose Quadrivalent Influenza Vaccine versus Standard Dose Quadrivalent Influenza Vaccine in Children 6 months to Less than 5 Years of Age No dispute reported 06/30/2026 691618003
Principal investigator 1 Merck Sharp & Dohme Corporation $1,500.00 01/11/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691307647
Principal investigator 1 Merck Sharp & Dohme Corporation $750.00 01/11/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691307691
Principal investigator 1 Merck Sharp & Dohme Corporation $20,925.26 01/11/2019 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691307723